Patent classifications
C07D235/04
ORGANIC ELECTROLUMINESCENT ELEMENT, COMPOUND AND ELECTRONIC DEVICE
An organic electroluminescence device includes: an anode; a cathode; and an emitting layer provided between the anode and the cathode, in which the emitting layer contains a delayed fluorescent compound M2 and a compound M3 represented by a formula (3) and a singlet energy S.sub.1(M2) of the compound M2 and a singlet energy S.sub.1(M3) of the compound M3 satisfy a relationship of a numerical formula (Numerical Formula 1) below, S.sub.1(M3)>S.sub.1(M2) . . . (Numerical Formula 1). In the formula (3), A3 is a group represented by a formula (3a) or the like.
##STR00001##
NOVEL BORATE COMPOUND-CONTAINING COMPOSITION
A borate compound-containing composition soluble in hydrocarbon solvents. A composition containing base A, or a compound having a total carbon number of not less than 8 and represented by the formula (5):
##STR00001##
wherein R and R′ are each independently an optionally substituted C.sub.1-30 alkyl group, an optionally substituted C.sub.3-15 cycloalkyl group, or an optionally substituted C.sub.6-14 aryl group; and
a borate compound represented by the following formula (1):
##STR00002##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently a C.sub.6-14 aryl group substituted by one or more fluorine atoms or fluoro C.sub.1-4 alkyl groups; and
[A-H].sup.+ is a base A-derived cation. A method for producing a polymer, by polymerizing at least one kind of monomer selected from the group consisting of olefins and dienes by using the composition A as a cocatalyst.
NOVEL BORATE COMPOUND-CONTAINING COMPOSITION
A borate compound-containing composition soluble in hydrocarbon solvents. A composition containing base A, or a compound having a total carbon number of not less than 8 and represented by the formula (5):
##STR00001##
wherein R and R′ are each independently an optionally substituted C.sub.1-30 alkyl group, an optionally substituted C.sub.3-15 cycloalkyl group, or an optionally substituted C.sub.6-14 aryl group; and
a borate compound represented by the following formula (1):
##STR00002##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently a C.sub.6-14 aryl group substituted by one or more fluorine atoms or fluoro C.sub.1-4 alkyl groups; and
[A-H].sup.+ is a base A-derived cation. A method for producing a polymer, by polymerizing at least one kind of monomer selected from the group consisting of olefins and dienes by using the composition A as a cocatalyst.
ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF
Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and/or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and/or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.
METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS
Methods, compounds, and compositions of conjugating anthracyclines to a carbohydrate polymer backbone via click chemistry are provided. The conjugation of anthracyclines utilizing a reaction between a hydrazone azide moiety and alkyne moiety provide for compositions with less crosslinking, and thereby increasing the efficacy of targeted drug delivery. The methods further provide for controlled loading of anthracycline to a carbohydrate polymer backbone.
METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS
Methods, compounds, and compositions of conjugating anthracyclines to a carbohydrate polymer backbone via click chemistry are provided. The conjugation of anthracyclines utilizing a reaction between a hydrazone azide moiety and alkyne moiety provide for compositions with less crosslinking, and thereby increasing the efficacy of targeted drug delivery. The methods further provide for controlled loading of anthracycline to a carbohydrate polymer backbone.
Phenylamine compounds
The present invention relates to 4-substituted phenylamidine derivatives of the general formula (I), wherein R5-R6, ArA4, D, G, B, Q and an integer m have the meanings as defined in the description. The invention further relates to methods for their preparation and use of said compounds for controlling undesired phytopathogenic microorganisms, and agents for said purpose, comprising said phenylamine derivatives. This invention further relates to a method for controlling undesired phytopathogenic microorganisms by application of said 4-substituted phenylamidine derivatives of general formula (I) to such undesired microorganisms and/or to their habitat, according to the invention.
Phenylamine compounds
The present invention relates to 4-substituted phenylamidine derivatives of the general formula (I), wherein R5-R6, ArA4, D, G, B, Q and an integer m have the meanings as defined in the description. The invention further relates to methods for their preparation and use of said compounds for controlling undesired phytopathogenic microorganisms, and agents for said purpose, comprising said phenylamine derivatives. This invention further relates to a method for controlling undesired phytopathogenic microorganisms by application of said 4-substituted phenylamidine derivatives of general formula (I) to such undesired microorganisms and/or to their habitat, according to the invention.
SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.
##STR00001##
SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.
##STR00001##